drugset / Trial / NCT01502202
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
RandomizedCrossoverQuadruple-blindTreatment
Summary
Intercalated administration of Iressa® (gefitinib) on days 5-18 of chemotherapy cycle improve the efficacy of Pemetrexed/platinum regimen given as first-line treatment for never-smokers with advanced (stage IIIB/IV) lung adenocarcinoma.
Timeline
- Start
- 2012-03
- Primary completion
- 2014-08
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gefitinib | Small molecule | 250 mg | Oral |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | — |